Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General)

ViiV Healthcare welcomes investigator-sponsored research that advances understanding of HIV treatment using other VH products besides Cabotegravir and Dolutegravir/Lamivudine. Research of interest may include real-world effectiveness, safety and tolerability, patient and provider experience, quality of life, healthcare resource use, economic value, and health equity. We encourage innovative approaches and studies across diverse populations that can expand real-world knowledge and inform clinical practice.

ViiV ISR Area Of Interest Overview

Drug/Product Alignment

ViiV Products in Scope:	Other
Treatment Type:	Treatment
Specify the Treatment Type:

Area of Interest/DataGap Description

Core Focus Area:	Open
Example Research Question(s):	All scientifically sound and relevant research questions that advance evidence in HIV treatment using other VH products besides Cabotegravir and Dolutegravir are welcome.

Desirable Study Parameters

Populations of Interest:	All Patient Types
Geographical Regions:	Global

Version 20250909-disp

- Back to Top -

Advancing Evidence in HIV Treatment: Using other VH Product besides Cabotegravir and Dolutegravir/Lamivudine (General)

ViiV ISR Area Of Interest Overview

Pure Substance Request

Investigator Sponsored Study (ISS)

Collaborative Study